Navigation Links
S*BIO Restructures Agreement With Onyx for JAK2 Inhibitor Program
Date:5/4/2011

SINGAPORE, May 4, 2011 /PRNewswire/ -- S*BIO Pte Ltd today announced the restructuring of its collaboration and option agreement with Onyx Pharmaceuticals, which was entered into in January 2009. As a result, S*BIO has regained North American and European rights to its novel JAK2 inhibitors, SB1518 and SB1578, from Onyx.  Following a successful and productive partnership with Onyx, S*BIO will now be in a position to drive the development of its lead JAK2 program independently.

Recent data from Phase 2 clinical trials of SB1518 indicated promising clinical efficacy and good tolerability for the treatment of myelofibrosis (MF), an orphan indication with high unmet medical need.  SB1518 has also demonstrated clinical benefits in patients with relapsed/refractory lymphoma. S*BIO plans to advance SB1518 and SB1578 expeditiously through clinical development, with pivotal trials for SB1518 anticipated to begin later this year.

"Consolidating North American and European rights for SB1518 and SB1578 represents a unique opportunity for S*BIO to steer the global development of these two promising products," said Dr. Jan-Anders Karlsson, CEO of S*BIO. "Our strong relationship with Onyx has led to the successful clinical advancement of both SB1518 and SB1578.  SB1518 has now reached a critical inflection point where its future success in a highly competitive field depends on an aggressive and focused development plan. As an existing shareholder, Onyx's interests remain aligned with S*BIO's objective to maximize the value of the JAK2 program and to share in the upside potential of SB1518 and other S*BIO assets."

About S*BIO Pte LtdS*BIO is a privately-held biotech company focused on the research and clinical development of novel targeted small molecule drugs for the treatment of cancer with leading programs around kinases and histone deacetylases (HDAC). SB1518, S*BIO's potent and orally-active JAK2 inhibitor, entered the clinic in 2008 and has now completed Phase 2 trials for MF.  It has received orphan drug designation from the U.S. and the E.U. regulatory authorities. S*BIO's lead HDAC inhibitor, SB939, is currently in Phase 2 trials. S*BIO's SB1317, a novel multikinase inhibitor, is in Phase 1 trials and under a worldwide exclusive license with Tragara Pharmaceuticals, Inc. for its development and commercialization.

In line with its vision to be a leading fully-integrated oncology-focused biotech company in Asia Pacific, S*BIO has established a state-of-the-art R&D infrastructure, complemented by a strong clinical development team. S*BIO has strong links with a network of medical oncologists in Asia Pacific and its investors include Bio*One Capital a subsidiary of EDBI (EDB Investments), Aravis Ventures, Mitsui Ventures, Novartis Bioventures and other international funds. In 2009, S*BIO received the BioSpectrum Editor's Choice, Emerging BioScience Company of Singapore Award. More information about S*BIO can be found at www.sbio.com.S*BIO Pte Ltd:Russo Partners:Hew Yin Chin, Ph.D.

Tony Russo +1 212-845-4251Associate Director, Corporate Development

Tony.Russo@russopartnersllc.com Tel: +65 6827 5000 (Singapore)

Andreas Marathovouniotis +1 212-845-4235yinchin_hew@sbio.com

Andreas.Marathis@russopartnersllc.com
'/>"/>

SOURCE S*BIO
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. S*BIO to Develop New JAK-2 Inhibitor for Treatment of Myeloproliferative Disorders and Hematological Malignancies
2. S*BIO Initiates U.S. Phase I Clinical Trials of Oral JAK2 Inhibitor SB1518 for the Treatment of Hematological Malignancies
3. S*BIO Advances JAK2 Inhibitor SB1518 into Phase 1/2 Clinical Trial in Australia for the Treatment of Chronic Idiopathic Myelofibrosis
4. S*BIOs JAK2 Inhibitor SB1518 Granted Orphan Drug Designation by European Commission (EC) for the Treatment of Myelofibrosis (MF)
5. S*BIOs Novel Dual mTOR/PI3 Kinase Inhibitor SB2343 Demonstrates Excellent PK/PD Properties Leading to Significant Anti-Tumor Efficacy in Xenograft Models
6. ImmuneRegen BioSciences Reports Material Transfer Agreement with VaxGen, Inc.
7. Quark Pharmaceuticals Extends Research Agreement with State University of New York for Proprietary siRNA Compounds for Acute Hearing Loss
8. CellCyte Genetics Corp. Enters Collaborative Research Agreement With Cleveland Clinic Foundation to Qualify Stem Cell Delivery in Damaged Heart Tissue
9. Intellect Neurosciences, Inc. and CHDI, Inc. Enter Into Compound Testing Agreement to Evaluate OXIGON(TM) as a Potential Treatment for Huntington Disease
10. Baxa Corporation Extends Global Reach With New Distribution Agreements in Colombia and the Dominican Republic
11. Quark Pharmaceuticals Signs Collaboration Agreement With University of Michigan for Development of Proprietary SiRNA Compounds for Noise-Induced Hearing Loss
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/9/2016)... Research and Markets has announced the addition of the ... ... vaccines market to grow at a CAGR of 6.83% during the ... the growth prospects of the global travel vaccines market for 2016-2020. ... from the sales of various vaccines administered to actively immunize meningococcal ...
(Date:12/8/2016)... IRIDEX Corporation (NASDAQ: IRIX ) today ... common stock, $0.01 par value (the "Offering" with such shares ... final terms of the Offering will depend on market and ... be no assurance as to whether or when the Offering ... net proceeds it will receive from this offering for working ...
(Date:12/8/2016)... , Dec. 8, 2016  The global biosurgery ... 8.8% during the forecast period of 2016 to 2021. ... by 2021 from USD 18.21 billion in 2016. The ... rising incidences of sports related injuries and spinal problems, ... rising need of effective blood loss management. ...
Breaking Medicine Technology:
(Date:12/9/2016)... , ... December 09, 2016 , ... ... at The Pierre Hotel in New York, NY, on December 3rd, to benefit ... and physicians attended the annual event, which raised over $1 million - the ...
(Date:12/8/2016)... ... December 08, 2016 , ... The Florida Hospital Tampa Wound ... Medical Society (UHMS), the leading authority in hyperbaric medicine. This accreditation identifies the ... hospitals and facilities have earned this distinction. This is the second time the ...
(Date:12/8/2016)... ... December 08, 2016 , ... ... Management (MTM), adherence, and other pharmacist-delivered patient care services, has announced the promotions ... Eric Hoessel to vice president of sales. , Litsinger joined Mirixa in ...
(Date:12/8/2016)... ... December 08, 2016 , ... ... access for customers and employees that are both engaging and easy to use. ... Smart Technology, the software company revealed today its plans to roll out new ...
(Date:12/8/2016)... ... December 08, 2016 , ... California Senate Bill (SB) 863, signed into law ... in 2013 and 2014, according to CompScope™ Medical Benchmarks for California, 17th Edition ... to the study, medical payments per claim in California decreased 4 percent in 2013 ...
Breaking Medicine News(10 mins):